Reckitt Benckiser Group Plc.OTCPK - Current
Advanced Chart
  • Mon, Oct. 24, 10:09 AM
    • BP (BP -0.7%) General Council Rupert Bondy will step down at the end of this year to join health and home products manufacturer Reckitt Benckiser (OTCPK:RBGPF) as senior VP, general council and company secretary.
    • Bondy joined BP in 2008 and was at the heart of several major legal processes with U.S. authorities and claimants following the 2010 Deepwater Horizon rig explosion which resulted in the worst oil spill in U.S. history.
    • BP says it has not yet named Bondy's successor.
    | Mon, Oct. 24, 10:09 AM | 4 Comments
  • Thu, May 19, 8:56 AM
    • Sterne Agee analyst April Scee says it makes more sense that Reckitt Benckiser (OTCPK:RBGLY, OTCPK:RBGPF) will make an offer for Church & Dwight (NYSE:CHD) than Procter & Gamble (NYSE:PG).
    • Though the P&G buyout speculation that drove Church & Dwight to a +20% premarket spike yesterday fizzled, there's still some leftover M&A intrigue around the company due to its strong presence in the U.S.
    • CHD +6.73% premarket to $103.51. For its part, Procter & Gamble is down 3% over the last few sessions with more retailers reporting tepid U.S. demand for consumer products.
    | Thu, May 19, 8:56 AM | 8 Comments
  • Dec. 29, 2015, 5:28 PM
    • Coffee prices continue to fall as strong El Nino rains in Brazil help to boost crop yields. The next harvest in the nation is forecast to be up 20% Y/Y at 58M bags.
    • Even with Arabica prices down 28% this year, analysts see another swing lower for coffee in 2016 due to the oversupply situation.
    • Weak currencies in South America are also providing a strong incentive to local producers to sell as much as they can.
    • The trend toward low coffee prices is helping to lift margins for many coffee sellers with U.S. retail prices only down 4% to 5% this year. Companies light on hedging positions are seeing the biggest benefit.
    • Most execs play coy over the bottom line benefit of lower coffee commodity prices, but even Starbucks CFO Scott Maw had to concede that pricing looked a "little bit favorable" during the firm's last earnings call (transcript).
    • Coffee futures chart
    | Dec. 29, 2015, 5:28 PM | 22 Comments
  • Nov. 19, 2015, 6:48 AM
    • The FDA approves privately held Adapt Pharma's Fast Track- and Priority Review-tagged NARCAN (naloxone hydrochloride) nasal spray for the treatment of opioid overdose. The product does not require assembly and can be administered by anyone, even those with no medical training. NARCAN is sprayed into one nostril while the patient is lying on his/her back and can be repeated if necessary. Immediate medical care is still required, however.
    • The FDA's action is a good example of the benefits of Priority Review and Fast Track. The PDUFA date was January 20.
    • Commercial launch will commence in early 2016.
    • Previously: FDA accepts for review Adapt Pharma's NDA for nasal spray treatment of opioid overdose (Sept. 24)
    • Related tickers: (OTCQB:LLTP)(OTCPK:RBGPF)(OTCPK:RBGLY)
    | Nov. 19, 2015, 6:48 AM | 9 Comments
  • Sep. 24, 2015, 12:07 PM
    | Sep. 24, 2015, 12:07 PM
  • Aug. 12, 2015, 7:35 AM
    • Reckitt Benckiser (OTCPK:RBGPF) (OTCPK:RBGLY) receives regulatory clearance from the UK's Competition and Markets Authority (CMA) to purchase Johnson & Johnson's (NYSE:JNJ) K-Y intimate lubricant business with the proviso that it license the brand to a third party for eight years. During this period, the company selling K-Y would create its own brand, after which Reckitt would resume control of K-Y.
    • Reckitt agreed to buy K-Y last year but encountered opposition from UK authorities who said the deal would reduce competition and result in higher prices for consumers. The CMA asked the company put forward measures to allay their concerns, but its initial proposals were unsuccessful.
    • The company's plan to purchase the K-Y business in New Zealand was also blocked due to anti-competitive concerns. Reckitt chief Rakesh Kapoor isn't too concerned since the bulk of K-Y sales come from the U.S., Canada and Brazil.
    • Under Mr. Kapoor, Reckitt is moving into higher margin consumer health products. The strategy appears to be working. H1 comps were up 13%.
    | Aug. 12, 2015, 7:35 AM
  • Jul. 27, 2015, 11:27 AM
    | Jul. 27, 2015, 11:27 AM
  • Jul. 1, 2015, 8:21 AM
    • J.M. Smucker (NYSE:SJM) cuts prices on packaged coffee products by an average of 6%.
    • The reduced pricing impacts products sold under the Folgers and Dunkin' Donuts brand names.
    • Wholesale coffee prices have moderated over the last six months (Robusta chart).
    | Jul. 1, 2015, 8:21 AM | 2 Comments
  • Apr. 24, 2015, 9:07 AM
    • Consumer products giant Reckitt Benckiser (OTCPK:RBGLY, OTCPK:RBGPF) reports revenue rose 5% (like-for-like) to £2.216B ($3.35B) in Q1 to top expectations.
    • Sales in North America were up 13% on a reported basis due to the impact of the strong U.S. dollar.
    • The company's pace of sales in emerging markets trailed peers, but its health unit provided a double-digit sales lift.
    • The company's says it on track to meet revenue targets and moderate to "nice" operating margin expansion.
    • Shares of Reckitt rose over 1% in London trading.
    • Reckitt Benckiser earnings release.
    | Apr. 24, 2015, 9:07 AM
  • Apr. 17, 2015, 10:39 AM
    • Heinz is making a big push into mustard in the U.S.
    • The Berkshire/3G company has launched its "Ketchup's Got a New Mustard" campaign with a strong focus on its mustard product's use of 100% natural ingredients.
    • Heinz and Kraft have a merger in the works that will give the combined company a big slice of the condiments market.
    • Major U.S. mustard sellers: Reckitt Benckiser (OTCPK:RBGLY, OTCPK:RBGPF), Kraft Foods (NASDAQ:KRFT), ConAgra (NYSE:CAG), and McCormick (NYSE:MCK).
    | Apr. 17, 2015, 10:39 AM | 13 Comments
  • Dec. 16, 2014, 10:26 AM
    • LightLake Therapeutics (OTCQB:LLTP +8.1%) enters into a license agreement with Adapt Pharma Limited subsidiary Adapt Pharma Operations Limited to develop and commercialize LightLake's intranasal naloxone opioid overdose reversal treatment. Under the terms of the contract, LightLake is eligible to receive as much as $55M in development- and sales-based milestones plus double-digit royalties.
    • In a clinical trial, data showed that LightLake's technology can potentially deliver naloxone into the blood stream as quickly as an injection, which is the current approach used by hospitals and first responders treating opioid overdoses. The company initiated a second study on December 4.
    • In May, Reckitt Benckiser (OTCPK:RBGPF) (OTCPK:RBGLY) (OTC:RBGPY) entered into a collaboration with Lexington, KY-based AntiOP to develop a naloxone nasal spray.
    • Previously: Reckitt Benckiser inks development deal for naloxone spray (May 19, 2014)
    | Dec. 16, 2014, 10:26 AM | 1 Comment
  • Nov. 17, 2014, 6:13 AM
    • Reckitt Benckiser (OTCPK:RBGLY) is planning to proceed with a spinoff of its pharmaceutical unit to existing shareholders next month.
    • Shareholders are expected to consider plans of the spinoff (to be called Indivior) at a meeting on Dec. 11. If approved, the business would begin trading on the London Stock Exchange on Dec. 23.
    • The pharmaceutical unit had revenue of $1.2B and profit of $489M in 2013, with about 80% of its revenue from the U.S.
    • Previously: Reckitt Benckiser to demerge pharmaceutical unit
    | Nov. 17, 2014, 6:13 AM | 1 Comment
  • Jul. 28, 2014, 4:48 AM
    • Reckitt Benckiser (OTCPK:RBGLY) states that it will pursue a demerger of its pharmaceutical division, allowing it to put a greater focus on its core consumer health and hygiene business.
    • The spinoff will occur in the next 12 months - becoming a separate U.K.-listed company.
    • The announcement follows the Reckitt Benckiser's 7% drop in second-quarter revenue which fell to £2.3B from £2.5B Y/Y.
    | Jul. 28, 2014, 4:48 AM
  • Jul. 21, 2014, 8:56 AM
    • German private equity firm Aurelius has agreed to buy Reckitt Benckiser's (OTCPK:RBGLY) Scholl shoe business. The company is expecting the brand to expand internationally and maintain growth.
    • Aurelius will acquire the international rights to the business, except for North and South America, which will go to Bayer (OTCPK:BAYRY) as part of its $14B purchase of Merck (NYSE:MRK).
    • The deal is expected to close in the third quarter of 2014.
    | Jul. 21, 2014, 8:56 AM | 1 Comment
  • Apr. 27, 2014, 1:23 AM
    • Merck (MRK) could agree a deal to sell its consumer healthcare operations this week for almost $14B, Reuters reports, with Germany's Bayer (BAYRY) and U.K.-based Reckitt Benckiser (RBGLY) the frontrunners to buy the unit.
    • Other healthcare consumer giants have also also shown interest in the business, including Procter & Gamble (PG), Novartis (NVS) and Sanofi (SNY).
    • Merck is looking to sell the operations as it only holds around 1% of the market.
    • A deal would be the latest in a wave of blockbuster transactions to have swept the healthcare sector recently, such as Pfizer's $100B+ reported offer to acquire AstroZeneca, Valeant and Bill Ackman's $47B play for Allergan, Zimmer's agreement to purchase Biomet for $13.35B, and a series of deals involving Novartis, GlaxoSmithKline and Eli Lilly.
    | Apr. 27, 2014, 1:23 AM
  • Apr. 22, 2014, 10:42 AM
    • WSJ's Hester Plumridge reports on the reasons GlaxoSmithKline (GSK +4.6%) exits the cancer space despite its substantial long-term growth prospects.
    • The move enables the firm to focus on its core businesses in respiratory, HIV, vaccines and consumer health with the intent of improving operating margins. These four areas constitute 70% of its revenue. The remaining 30% is evenly split between its legacy products and metabolic/cardiovascular. It intends to retain the latter and divest the former.
    • The $16B sale of its cancer business to Novartis (NVS +1.5%) delivers substantial value for shareholders considering its relatively modest top line of $1.6B and the lack of promising immunotherapies. Glaxo ranks a distant fourteenth in market share with little hope of making headway versus the dominant players.
    • Earlier this month, Glaxo stopped the development of IMAGE-A3, its once-promising cancer vaccine. The firm will continue some cancer-related R&D but Novartis will have commercial rights to all future products.
    • With the inclusion of Novartis' vaccine business Glaxo is the global leader in market share and scale.
    • The consumer health joint venture will have the heft to compete more effectively with Reckitt Benckiser Group (RBGPF +0.1%), Colgate-Palmolive (CL -0.5%) and Unilver (UN +0.1%). Glaxo is the dominant partner with a 63.5% stake. It has the option of buying out its partners or selling its holdings in three years.
    • Glaxo expects to save ~$1.3B per year due to improved operational efficiency in vaccines and consumer health.
    | Apr. 22, 2014, 10:42 AM